About YZY Biopharma
YZY Biopharma (02496.HK) develops bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and geriatric ophthalmology to solve oncology and geriatric ophthalmology problems. It helps to solve medical needs in these fields of diseases by using biotechnology to develop drugs and vaccines. The company was founded in 2010 and is based in Wuhan, China.
Latest YZY Biopharma News
Sep 26, 2023
Sep. 26, 2023 Wuhan YZY Biopharma Co. Ltd. made its debut on the Hong Kong Stock Exchange, raising HK$121 million (US$15.48 million) in its IPO on Sept. 22, with shares (HKEX:02496) opening at the lower end of its range at HK$16 per share and ending the day at HK$16.60, a rise of 3.75%.
YZY Biopharma Frequently Asked Questions (FAQ)
When was YZY Biopharma founded?
YZY Biopharma was founded in 2010.
Where is YZY Biopharma's headquarters?
YZY Biopharma's headquarters is located at No. 666 Gaoxin Avenue, East Lake New Technology Development Zone, Wuhan.
What is YZY Biopharma's latest funding round?
YZY Biopharma's latest funding round is IPO.
How much did YZY Biopharma raise?
YZY Biopharma raised a total of $140.51M.
Who are the investors of YZY Biopharma?
Investors of YZY Biopharma include Optics Valley Financial Holding Group, Wuhan Hi-Tech, Hubei Science & Technology Investment Group, TD Capital, Camel Fund and 12 more.